Psychiatric medication management for Fort Lauderdale — measurement-based, in-person.

Fort Lauderdale adults who have cycled through two SSRIs at primary care and stalled need a psychiatrist willing to work the full algorithm — augmentation, class switching, and escalation to TMS or Spravato when indicated. RECO Integrated Psychiatry is 26 miles up I-95 in Delray Beach — about 40 minutes from Las Olas or Victoria Park — runs 60-90 minute initial evaluations, and anchors every follow-up to PHQ-9 and GAD-7 trajectory rather than clinical impression alone.

From Las Olas, Victoria Park, Coral Ridge, or Rio Vista, RECO Integrated Psychiatry sits 26 miles up I-95 in Delray Beach — roughly a 40-minute drive that many Fort Lauderdale adults find worth the trip when primary care has run out of medication options and the local psychiatry waitlists stretch three to four months. This page explains what outpatient psychiatric medication management looks like when it is done as a specialty service rather than as a 15-minute refill visit, and what a Fort Lauderdale client can expect from the diagnostic evaluation, the pharmacologic algorithm, and the monitoring cadence.

RECO provides outpatient psychiatric medication management for major depressive disorder, bipolar I and II, generalized and panic anxiety, PTSD, adult ADHD, and OCD. The practice is built around a documented DSM-5-TR formulation, measurement-based care with PHQ-9 and GAD-7 tracked at every visit, and the full pharmacologic toolkit — augmentation, class switching, pharmacogenomic testing, and interventional escalation to TMS or Spravato when indicated.

What a real psychiatric evaluation actually covers

The initial visit runs 60 to 90 minutes and produces a written DSM-5-TR diagnostic formulation, not a symptom checklist. History includes every prior psychotropic trial with dose, duration, and the specific reason for discontinuation — “it didn’t work” gets unpacked into whether the client reached a therapeutic dose (e.g., sertraline 150-200 mg, venlafaxine XR 225 mg, bupropion XL 450 mg), for how many weeks, and whether the discontinuation was for lack of response, adverse effect, or non-adherence. Family psychiatric history is documented across first- and second-degree relatives, with attention to lithium responsiveness, completed suicide, and psychiatric hospitalization.

Every client presenting with “depression” or “anxiety” is screened for bipolarity with the MDQ, for adult ADHD with the ASRS, and for OCD with a Y-BOCS symptom checklist. Trauma history is taken where clinically relevant. Substance use is screened with AUDIT-C and a directed drug-use interview. Baseline labs — CBC, CMP, TSH, B12, folate, vitamin D, HbA1c, and lipid panel where the differential includes a mood or psychotic disorder — are ordered before or at the first follow-up. This is the visit primary care does not have room to run.

Measurement-based care and why it changes outcomes

PHQ-9 for depression, GAD-7 for anxiety, MDQ for bipolar screening, ASRS for ADHD, and Y-BOCS for OCD are completed by the client before each visit, scored in the visit, and plotted longitudinally. The published evidence — including the STAR*D secondary analyses and multiple pragmatic trials in outpatient psychiatry — is that measurement-based care produces meaningfully better remission rates than clinical impression alone. It also protects against the two most common medication-management errors: staying too long on a partial responder because the client is politely reporting “a little better,” and switching too early off a medication that has not yet reached its response window.

At RECO, the medication decision at each follow-up is anchored to the scale trajectory. A PHQ-9 that has dropped from 19 to 14 after six weeks on sertraline 100 mg is a partial response that warrants a dose increase, not a switch. A GAD-7 unchanged at 16 after eight weeks at an adequate SNRI dose triggers a defined next step — augmentation with buspirone, cross-taper to a different agent, or an add-on such as hydroxyzine or gabapentin — rather than another “let’s give it more time.”

The pharmacologic toolkit beyond the first two SSRIs

First-line pharmacotherapy is not controversial. SSRIs and SNRIs are first-line for depression and anxiety; stimulants (methylphenidate, mixed amphetamine salts) and non-stimulants (atomoxetine, viloxazine, guanfacine) for ADHD; lithium, valproate, lamotrigine, and atypicals (quetiapine, lurasidone, aripiprazole, cariprazine) for bipolar disorder; SSRIs at high doses plus ERP referral for OCD. The value of specialty psychiatry shows up after first-line fails.

That toolkit includes augmentation with aripiprazole, brexpiprazole, or low-dose lithium in treatment-resistant depression; thyroid augmentation with T3 where appropriate; strategic switching within class (sertraline to escitalopram) or across class (SSRI to SNRI to bupropion to mirtazapine) with documented rationale; MAOIs (tranylcypromine, phenelzine) where indicated and washout periods respected; pharmacogenomic testing (GeneSight, Genomind) reserved for genuinely complex cases rather than deployed reflexively; and appropriate escalation to rTMS (typical protocol 3,000 pulses per session at 120% of motor threshold over 36 sessions) or esketamine (Spravato) for treatment-resistant depression meeting FDA criteria.

Monitoring: the labs, the metabolic panel, the drug levels

Medication management is not just prescribing — it is the monitoring that makes prescribing safe. Lithium requires a baseline TSH, creatinine, calcium, and pregnancy test; a 12-hour trough level five to seven days after any dose change; and quarterly levels once stable, with annual TSH and renal function. Atypical antipsychotics require baseline weight, waist circumference, blood pressure, fasting glucose or HbA1c, and lipid panel, repeated at 12 weeks and then annually per APA metabolic monitoring guidance.

Valproate requires baseline LFTs, CBC with platelets, and levels drawn as a 12-hour trough. Lamotrigine requires a strict titration schedule (25 mg for two weeks, 50 mg for two weeks, then upward) with client education on rash. Stimulants require a cardiovascular history, baseline and interval blood pressure and pulse, and a controlled-substance treatment agreement. RECO builds these into the visit cadence so that nothing gets missed because the client did not know to ask.

Coordination with therapy and interventional care

Medication is one lever. For most clients, the best outcomes come from pairing pharmacotherapy with an evidence-based psychotherapy — CBT for depression and anxiety, ERP for OCD, EMDR or trauma-focused CBT for PTSD, DBT skills for emotion dysregulation and self-harm risk, ACT and MI where indicated. RECO coordinates with the client’s existing therapist or refers into a vetted network in Broward and Palm Beach counties. For clients who have failed two or more adequate antidepressant trials, RECO’s on-site TMS and Spravato programs allow escalation without a second referral.

What to expect on your first visit

Plan for 75 to 90 minutes on-site in Delray Beach. Bring a written or photographed list of every psychotropic ever tried, dose, duration, and reason stopped; current medications including supplements; and any recent labs. You will complete PHQ-9, GAD-7, MDQ, ASRS, and AUDIT-C in the portal beforehand. You leave with a written diagnostic impression, a medication plan, a lab order where indicated, and a follow-up scheduled at two to four weeks — sooner for a new stimulant, lithium, or antipsychotic start.

Insurance and admissions from Fort Lauderdale

RECO is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans. Copays and coinsurance vary by plan; the admissions team runs a verification of benefits before the first visit and quotes the client’s specific out-of-pocket exposure in writing. Fort Lauderdale clients typically schedule morning appointments to avoid I-95 southbound traffic on the return.

Serving residents of: Las Olas, Victoria Park, Coral Ridge, Rio Vista, Wilton Manors.